



Universiteit
Leiden
The Netherlands

"Prostaglandin F-2 alpha-induced prostate transmembrane protein, androgen induced 1 mediate ovarian cancer progression increasing epithelial plasticity"

Jimenez-Segovia, A.; Mota, A.; Rojo-Sebastian, A.; Barrocal, B.; Rynne-Vidal, A.; Garcia-Bermejo, M.L.; ... ; Stamatakis, K.

Citation


Jimenez-Segovia, A., Mota, A., Rojo-Sebastian, A., Barrocal, B., Rynne-Vidal, A., Garcia-Bermejo, M. L., ... Stamatakis, K. (2020). "Prostaglandin F-2 alpha-induced prostate transmembrane protein, androgen induced 1 mediate ovarian cancer progression increasing epithelial plasticity". *Neoplasia*, 22(5), 217-219. doi:10.1016/j.neo.2020.03.003

Version: Publisher's Version

License: [Creative Commons CC BY-NC-ND 4.0 license](https://creativecommons.org/licenses/by-nc-nd/4.0/)

Downloaded from: <https://hdl.handle.net/1887/3182030>

Note: To cite this publication please use the final published version (if applicable).

**Corrigendum to “Prostaglandin
F_{2α}-induced prostate transmembrane
protein, androgen induced 1 mediates
ovarian cancer progression increasing
epithelial plasticity” [Neoplasia 21
(2019) 1073–1084]** 

**Alba Jiménez-Segovia^a; Alba Mota^{b,c};
Alejandro Rojo-Sebastián^{c,d}; Beatriz Barrocal^a;
Angela Rynne-Vidal^a; María-Laura García-Bermejo^a;
Raquel Gómez-Bris^a; Lukas J.A.C. Hawinkels^f;
Pilar Sandoval^a; Ramon Garcia-Escudero^{d,g,h};
Manuel López-Cabrera^a; Gema Moreno-Bueno^{b,c,d};
Manuel Fresno^{a,i,*}; Konstantinos Stamatakis^{a,j,*}**

^aCentro de Biología Molecular “Severo Ochoa” (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), ^{c/} Nicolás Cabrera, 1, Campus Cantoblanco, Universidad Autónoma de Madrid, Madrid 28049, Spain; ^bDepartamento de Bioquímica, Universidad Autónoma de Madrid (UAM), Instituto de Investigaciones Biomédicas ‘Alberto Sols’ (CSIC-UAM), IdiPaz, Madrid, Spain ^eMD Anderson Cancer Center Madrid & Fundación MD Anderson Internacional, Madrid, Spain; ^dCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Spain ^eBiomarkers and Therapeutic Targets Lab, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain ^fDepartment of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, the Netherlands ^gMolecular Oncology Unit, CIEMAT, Madrid, Spain; ^hBiomedical Research Institute I+12, University Hospital 12 de Octubre, Madrid 28041, Spain; ⁱInstituto de Investigación Sanitaria Hospital Universitario de la Princesa (IIS-P), Madrid, Spain

The authors regret the errors in three figure panels: A repeated (HSP90) and a wrong (β-catenin) panel in Fig. 4D and a repeated panel in Fig. 5C (HSP90). The corrected figures are as below. The authors believe these errors and corrections do not affect the article's conclusions.


DOI of original article: <https://doi.org/10.1016/j.neo.2019.10.001>


* Corresponding authors at: Centro de Biología Molecular “Severo Ochoa” (Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid), ^{c/} Nicolás Cabrera, 1, Campus Cantoblanco, Universidad Autónoma de Madrid, Madrid 28049, Spain.

e-mail addresses: mfresno@cbm.csic.es (M. Fresno), k.s@csic.es (K. Stamatakis).

© 2019 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<https://doi.org/10.1016/j.neo.2020.03.003>





The authors would like to apologise for any inconvenience caused.